U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H31F3O5S
Molecular Weight 500.571
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Fluticasone Propionate

SMILES

CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF

InChI

InChIKey=WMWTYOKRWGGJOA-CENSZEJFSA-N
InChI=1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/fluticasone.html

Fluticasone propionate, a medium-potency synthetic corticosteroid, is used topically to relieve inflammatory and pruritic symptoms of dermatoses and psoriasis, intranasally to manage symptoms of allergic and non-allergic rhinitis, and orally for the treatment of asthma. Fluticasone proprionate is marketed under several different brand names such as Flonase®. Fluticasone propionate is also available as a combination product of azelastine hydrochloride and fluticasone propionate called Dymista™. Dymista™ is indicated in patients over 12 years old for symptomatic relief of seasonal allergic rhinitis. Fluticasone propionate binds to the glucocorticoid receptor. Unbound corticosteroids cross the membranes of cells such as mast cells and eosinophils, binding with high affinity to glucocorticoid receptors (GR). The results include alteration of transcription and protein synthesis, a decreased release of leukocytic acid hydrolases, reduction in fibroblast proliferation, prevention of macrophage accumulation at inflamed sites, reduction of collagen deposition, interference with leukocyte adhesion to the capillary wall, reduction of capillary membrane permeability and subsequent edema, reduction of complement components, inhibition of histamine and kinin release, and interference with the formation of scar tissue. In the management of asthma, the glucocorticoid receptor complexes down-regulates proinflammatory mediators such as interleukin-(IL)-1, 3, and 5, and up-regulates anti-inflammatory mediators such as IkappaB [inhibitory molecule for nuclear factor kappaB1], IL-10, and IL-12. The antiinflammatory actions of corticosteroids are also thought to involve inhibition of cytosolic phospholipase A2 (through activation of lipocortin-1 (annexin)) which controls the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.

CNS Activity

Originator

Approval Year

1990
111
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
 1.0 nM [EC50]
Agonist
2752
 0.7 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
CUTIVATE

Approved Use

CUTIVATE® Ointment is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in adult patients.

Launch Date

1990
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
23364 pg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/12680886
1000 μg single, intravenous
dose: 1000 μg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FLUTICASONE PROPIONATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
14148 pg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/12680886
1000 μg single, intravenous
dose: 1000 μg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FLUTICASONE PROPIONATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.1 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/12680886
1000 μg single, intravenous
dose: 1000 μg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FLUTICASONE PROPIONATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
9%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/076633_ORIGINAL%20APPROVAL_PACKAGE.pdf
1 mg single, intravenous
dose: 1 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FLUTICASONE PROPIONATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
16 mg single, oral
Highest studied dose
Dose: 16 mg
Route: oral
Route: single
Dose: 16 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf
healthy, adult
Health Status: healthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf
2 mg 2 times / day multiple, intranasal
Highest studied dose
Dose: 2 mg, 2 times / day
Route: intranasal
Route: multiple
Dose: 2 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf
healthy, adult
Health Status: healthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf
80 mg 1 times / day multiple, oral
Highest studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf
healthy, adult
Health Status: healthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf
1320 ug 1 times / day multiple, respiratory
Highest studied dose
Dose: 1320 ug, 1 times / day
Route: respiratory
Route: multiple
Dose: 1320 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20548slr020,20121slr030_flovent_lbl.pdf
healthy, adult
Health Status: healthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20548slr020,20121slr030_flovent_lbl.pdf
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20548slr020,20121slr030_flovent_lbl.pdf
3520 ug single, respiratory
Highest studied dose
Dose: 3520 ug
Route: respiratory
Route: single
Dose: 3520 ug
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20548slr020,20121slr030_flovent_lbl.pdf
healthy, adult
Health Status: healthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20548slr020,20121slr030_flovent_lbl.pdf
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20548slr020,20121slr030_flovent_lbl.pdf
25 ug 2 times / day steady, respiratory
Dose: 25 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 25 ug, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02980133
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://clinicaltrials.gov/ct2/show/NCT02980133
Other AEs: Pneumonia mycoplasmal...
Other AEs:
Pneumonia mycoplasmal (serious, 1 patient)
Sources:
https://clinicaltrials.gov/ct2/show/NCT02980133
50 ug 2 times / day steady, respiratory
Dose: 50 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 50 ug, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02980133
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://clinicaltrials.gov/ct2/show/NCT02980133
Other AEs: Disruptive mood dysregulation disorder...
Other AEs:
Disruptive mood dysregulation disorder (serious, 1 patient)
Sources:
https://clinicaltrials.gov/ct2/show/NCT02980133
200 ug 1 times / day steady, intranasal
Dose: 200 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 200 ug, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01817790
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT01817790
Other AEs: Thirst, Gastrointestinal viral infection...
Other AEs:
Thirst (below serious, 1 patient)
Gastrointestinal viral infection (below serious, 1 patient)
Headache (below serious, 2 patients)
Throat irritation (below serious, 1 patient)
Palpitations (below serious, 1 patient)
Laceration (below serious, 1 patient)
Hypertension (below serious, 1 patient)
Sources:
https://clinicaltrials.gov/ct2/show/NCT01817790
880 ug 2 times / day steady, oral
Dose: 880 ug, 2 times / day
Route: oral
Route: steady
Dose: 880 ug, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00275561
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00275561
Other AEs: Esophageal candidiasis...
Other AEs:
Esophageal candidiasis (below serious, 5 patients)
Sources:
https://clinicaltrials.gov/ct2/show/NCT00275561
880 ug 2 times / day steady, oral
Dose: 880 ug, 2 times / day
Route: oral
Route: steady
Dose: 880 ug, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00426283
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00426283
Other AEs: General system disorders NEC, General system disorders NEC...
Other AEs:
General system disorders NEC (below serious, 7 patients)
General system disorders NEC (below serious, 2 patients)
General system disorders NEC (below serious, 1 patient)
General system disorders NEC (below serious, 5 patients)
General system disorders NEC (below serious, 4 patients)
Sources:
https://clinicaltrials.gov/ct2/show/NCT00426283
AEs

AEs

AESignificanceDosePopulation
Pneumonia mycoplasmal serious, 1 patient
25 ug 2 times / day steady, respiratory
Dose: 25 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 25 ug, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02980133
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://clinicaltrials.gov/ct2/show/NCT02980133
Disruptive mood dysregulation disorder serious, 1 patient
50 ug 2 times / day steady, respiratory
Dose: 50 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 50 ug, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02980133
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://clinicaltrials.gov/ct2/show/NCT02980133
Gastrointestinal viral infection below serious, 1 patient
200 ug 1 times / day steady, intranasal
Dose: 200 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 200 ug, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01817790
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT01817790
Hypertension below serious, 1 patient
200 ug 1 times / day steady, intranasal
Dose: 200 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 200 ug, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01817790
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT01817790
Laceration below serious, 1 patient
200 ug 1 times / day steady, intranasal
Dose: 200 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 200 ug, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01817790
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT01817790
Palpitations below serious, 1 patient
200 ug 1 times / day steady, intranasal
Dose: 200 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 200 ug, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01817790
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT01817790
Thirst below serious, 1 patient
200 ug 1 times / day steady, intranasal
Dose: 200 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 200 ug, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01817790
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT01817790
Throat irritation below serious, 1 patient
200 ug 1 times / day steady, intranasal
Dose: 200 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 200 ug, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01817790
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT01817790
Headache below serious, 2 patients
200 ug 1 times / day steady, intranasal
Dose: 200 ug, 1 times / day
Route: intranasal
Route: steady
Dose: 200 ug, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01817790
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT01817790
Esophageal candidiasis below serious, 5 patients
880 ug 2 times / day steady, oral
Dose: 880 ug, 2 times / day
Route: oral
Route: steady
Dose: 880 ug, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00275561
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00275561
General system disorders NEC below serious, 1 patient
880 ug 2 times / day steady, oral
Dose: 880 ug, 2 times / day
Route: oral
Route: steady
Dose: 880 ug, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00426283
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00426283
General system disorders NEC below serious, 2 patients
880 ug 2 times / day steady, oral
Dose: 880 ug, 2 times / day
Route: oral
Route: steady
Dose: 880 ug, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00426283
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00426283
General system disorders NEC below serious, 4 patients
880 ug 2 times / day steady, oral
Dose: 880 ug, 2 times / day
Route: oral
Route: steady
Dose: 880 ug, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00426283
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00426283
General system disorders NEC below serious, 5 patients
880 ug 2 times / day steady, oral
Dose: 880 ug, 2 times / day
Route: oral
Route: steady
Dose: 880 ug, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00426283
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00426283
General system disorders NEC below serious, 7 patients
880 ug 2 times / day steady, oral
Dose: 880 ug, 2 times / day
Route: oral
Route: steady
Dose: 880 ug, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00426283
unhealthy
Health Status: unhealthy
Sources:
https://clinicaltrials.gov/ct2/show/NCT00426283
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2252

substrate
1946
substrate
1193
substrate
1388

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP3A5
136
CYP1A1
389

CYP1A2
1197

CYP1B1
104

CYP2A6
626

CYP2B6
776

CYP2C8
810

CYP2C18
149

CYP2C19
1119

CYP2E1
729

CYP3A5
446

CYP3A7
109

P-gp
2052
P-gp
301
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
2633
 weak
CYP3A5
201
 yes
P-gp
1932
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP1A1
389
 no
CYP1A2
1197
 no
CYP1B1
104
 no
CYP2A6
626
 no
CYP2B6
776
 no
CYP2C18
149
 no
CYP2C19
1119
 no
CYP2C8
810
 no
CYP2C9
1193
 no
CYP2D6
1388
 no
CYP2E1
729
 no
P-gp
2052
 weak
CYP3A5
446
 yes [Km 3.8 uM]
CYP3A7
109
 yes [Km 5.2 uM]
CYP3A4
1946
 yes [Km 5.3 uM]
yes (co-administration study)
Comment: Ritonavir A drug interaction trial with fluticasone propionate aqueous nasal spray in healthy subjects has shown that ritonavir (a strong CYP3A4 inhibitor) can significantly increase plasma fluticasone propionate exposure, resulting in significantly reduced serum cortisol concentrations
Page: 14.0
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:31441
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31441
ChemicalBook
CB1252206
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1252206
ChemicalBook
CB52622685
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB52622685
ChemicalBook
CB5274961
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5274961
ChemicalBook
CB94798094
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB94798094
eMolecules
2736271
https://www.emolecules.com/cgi-bin/more?vid=2736271
eMolecules
31226118
https://www.emolecules.com/cgi-bin/more?vid=31226118
MolPort
MolPort-003-847-468
https://www.molport.com/shop/molecule-link/MolPort-003-847-468
Selleck Chemicals
fluticasone-propionate-Flonase-Veramyst
http://www.selleckchem.com/products/fluticasone-propionate-Flonase-Veramyst.html
ZINC
ZINC000003920027
http://zinc15.docking.org/substances/ZINC000003920027
PubMed

PubMed

TitleDatePubMed
One-year treatment with different dosing schedules of fluticasone propionate in childhood asthma. Effects on hyperresponsiveness, lung function, and height.
2001-12-01
The cost effectiveness of early treatment with fluticasone propionate 250 microg twice a day in subjects with obstructive airway disease. Results of the DIMCA program.
2001-12-01
Cost-effectiveness of fluticasone propionate administered via metered-dose inhaler plus babyhaler spacer in the treatment of asthma in preschool-aged children.
2001-12
Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis.
2001-11-26
Beclomethasone, budesonide and fluticasone propionate inhibit human neutrophil apoptosis.
2001-11-23
Novel anti-inflammatory effects of the inhaled corticosteroid fluticasone propionate during lung myofibroblastic differentiation.
2001-11-01
Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler.
2001-11
Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients.
2001-11
Effects of 2 inhaled corticosteroids on growth: results of a randomized controlled trial.
2001-11
Comparison of the tissue affinity of glucocorticoids to human lung, nasal and skin tissue in vitro.
2001-10
The effect of low-dose inhaled fluticasone propionate on exhaled nitric oxide in asthmatic patients and comparison with oral zafirlukast.
2001-10
Fluticasone propionate aqueous nasal spray in pregnancy rhinitis.
2001-10
[Combination treatment with inhaled corticosteroid/long-acting beta 2-adrenergic bronchodilator in the treatment of asthma].
2001-10
[Japanese guideline for the diagnosis and management of bronchial asthma (1998)--its results and reversion].
2001-10
Serum dehydroepiandrosterone sulfate concentration as an indicator of adrenocortical suppression in asthmatic children treated with inhaled steroids.
2001-10
Response of preschool children with asthma symptoms to fluticasone propionate.
2001-10
Quantification of epimeric budesonide and fluticasone propionate in human plasma by liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry.
2001-09-25
Intracranial hypertension and nasal fluticasone propionate.
2001-09-22
Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta(2)-agonists alone.
2001-09-01
A comparison of asthma-related expenditures for patients started on montelukast versus fluticasone propionate as monotherapy.
2001-09
A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate.
2001-09
Improved safety with equivalent asthma control in adults with chronic severe asthma on high-dose fluticasone propionate.
2001-09
The penetration of 0.005% fluticasone propionate ointment in eyelid skin.
2001-09
A comparison of short-term treatment with inhaled fluticasone propionate and zafirlukast for patients with persistent asthma.
2001-08-15
Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis.
2001-08-04
Improvement in health care utilization and pulmonary function with fluticasone propionate in patients with steroid-dependent asthma at a National Asthma Referral Center.
2001-08
Effects of single-dose fluticasone on exercise-induced asthma in asthmatic children: a pilot study.
2001-08
Fluticasone propionate and budesonide do not influence bone metabolism in the long term treatment of asthma.
2001-07-14
Fluticasone and salmeterol downregulate in vitro, fibroblast proliferation and ICAM-1 or H-CAM expression.
2001-07
Drugs for the treatment of allergic diseases.
2001-07
Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial.
2001-07
Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate.
2001-07
Effects of intranasal corticosteroids on the hypothalamic-pituitary-adrenal axis in children.
2001-07
Pharmacokinetics of intranasal corticosteroids.
2001-07
A novel pharmacologic action of glucocorticosteroids on leukotriene C4 catabolism.
2001-07
GRbeta expression in nasal polyp inflammatory cells and its relationship to the anti-inflammatory effects of intranasal fluticasone.
2001-07
Improved asthma control after changing from low-to-medium doses of other inhaled corticosteroids to low-dose fluticasone propionate.
2001-06-08
A comparison of clinical use of fluticasone propionate and beclomethasone dipropionate in pediatric asthma.
2001-06
[Effect of FP inhalation and airway inflammation assessed by ECP in asthma].
2001-06
[Peak inspiratory flow rates attained by asthmatic patients through a dry-powder inhaler of fluticasone propionate].
2001-06
Topical corticosteroids in chronic rhinosinusitis: a randomized, double-blind, placebo-controlled trial using fluticasone propionate aqueous nasal spray.
2001-06
Small airway inflammation in asthma.
2001
Using clinical measures of disease control to reduce the burden of asthma.
2001
Inhaled fluticasone propionate for chronic asthma.
2001
Aerosol characterization of nebulized intranasal glucocorticoid formulations.
2001
Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma.
2001
Should inhaled corticosteroids be used in the long term treatment of chronic obstructive pulmonary disease?
2001
Clinical prescribing of allergic rhinitis medication in the preschool and young school-age child: what are the options?
2001
Systemic availability of inhaled budesonide and fluticasone propionate: healthy versus asthmatic lungs.
2001
Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma.
2001
Patents

Patents

JP2001139474A
10
JP2001231861A
1
JP2001508034A
1
JP2001525058A
71
JP2002506696A
1
JP2002507471A
1
JP2002513391A
22
JP2002537249A
4
JP2002542293A
14
JP2003055206A
4
JP2003512892A
5
JP2003515526A
470
JP2003523267A
1
JP2004505900A
6
JP2004528150A
1
JP2004528151A
1
JP2004538241A
1
JP2005511210A
3
JP2005515848A
8
JP2006501253A
6
JP2006503054A
1
JP2006520379A
75
JP2006523630A
1
JP2006526624A
22
JP2007106777A
1
JP2007262064A
2
JP2007500147A
8
JP2007500150A
28
JP2007501194A
4
JP2007505928A
12
JP2007507270A
5
JP2007508363A
3
JP2007512337A
4
JP2007512898A
7
JP2007513165A
55
JP2007516217A
14
JP2007517067A
31
JP2007518817A
5
JP2007520508A
6
JP2007527381A
13
JP2008056698A
1
JP2008156327A
1
JP2008510795A
76
JP2009521489A
4
JP2009526755A
475
JP2009534333A
15
JP2010070567A
2
JP2010111592A
1
JP2010506837A
76
JP2010506941A
4
JP2011121972A
1

Sample Use Guides

In Vivo Use Guide
Usual Adult Dose for Dermatitis Cream/Ointment: Apply a thin film to affected area twice a day
Route of Administration: Topical
In Vitro Use Guide
Pretreatment with Fluticasone propionate (10(-11) M to about 10(-7) M, 24 h) inhibited TNF-alpha-induced VCAM-1 mRNA expression in BEAS-2B in a dose-dependent manner
Name Type Language
Fluticasone Propionate
EP   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
ADVAIR HFA COMPONENT FLUTICASONE PROPIONATE
Preferred Name English
FLUTICASONE PROPIONATE [ORANGE BOOK]
Common Name English
ADVAIR COMPONENT FLUTICASONE PROPIONATE
Brand Name English
FLUTICASONE PROPIONATE [USP MONOGRAPH]
Common Name English
CUTIVATE
Brand Name English
S-FLUOROMETHYL 6.ALPHA., 9.ALPHA.-DIFLUORO-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-17.ALPHA.-PROPIONYLOXYANDROSTA-1,4-DIENE-17.BETA-. CARBOTHIOATE
Common Name English
FLIXOTIDE
Brand Name English
FLUTICASONE PROPIONATE [EP MONOGRAPH]
Common Name English
ARMONAIR RESPICLICK
Brand Name English
LIPO-102 COMPONENT FLUTICASONE PROPIONATE
Common Name English
FLUTICASONE PROPIONATE [JAN]
Common Name English
FLOVENT
Code English
CCI18781
Code English
FLUTICASONE PROPIONATE [USP-RS]
Common Name English
PF-00241939
Code English
FLUTICASONE PROPIONATE [MART.]
Common Name English
AIRDUO RESPICLICK COMPONENT FLUTICASONE PROPIONATE
Brand Name English
NSC-759889
Code English
DYMISTA COMPONENT FLUTICASONE PROPIONATE
Common Name English
FLUTICASONE PROPIONATE [USAN]
Common Name English
CCI-18781
Code English
XHANCE
Brand Name English
Fluticasone propionate [WHO-DD]
Common Name English
ANDROSTA-1,4-DIENE-17-CARBOTHIOIC ACID, 6,9-DIFLUORO-11-HYDROXY-16-METHYL-3-OXO-17-(1-OXOPROPOXY)-, (6.ALPHA.,11.BETA.,16.ALPHA.,17.ALPHA.)-S-(FLUOROMETHYL) ESTER
Common Name English
FLUTICASONE PROPIONATE [MI]
Common Name English
FLUTICASONE-17-PROPIONATE
Common Name English
FLUTICASONE PROPIONATE [VANDF]
Common Name English
FLONASE
Brand Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 273208
Created by admin on Mon Mar 31 17:50:59 GMT 2025 , Edited by admin on Mon Mar 31 17:50:59 GMT 2025
EU-Orphan Drug EU/3/16/1815
Created by admin on Mon Mar 31 17:50:59 GMT 2025 , Edited by admin on Mon Mar 31 17:50:59 GMT 2025
FDA ORPHAN DRUG 319410
Created by admin on Mon Mar 31 17:50:59 GMT 2025 , Edited by admin on Mon Mar 31 17:50:59 GMT 2025
FDA ORPHAN DRUG 499815
Created by admin on Mon Mar 31 17:50:59 GMT 2025 , Edited by admin on Mon Mar 31 17:50:59 GMT 2025
NCI_THESAURUS C521
Created by admin on Mon Mar 31 17:50:59 GMT 2025 , Edited by admin on Mon Mar 31 17:50:59 GMT 2025
Code System Code Type Description
PUBCHEM
444036
Created by admin on Mon Mar 31 17:50:59 GMT 2025 , Edited by admin on Mon Mar 31 17:50:59 GMT 2025
PRIMARY
EVMPD
SUB02241MIG
Created by admin on Mon Mar 31 17:50:59 GMT 2025 , Edited by admin on Mon Mar 31 17:50:59 GMT 2025
PRIMARY
MERCK INDEX
m5510
Created by admin on Mon Mar 31 17:50:59 GMT 2025 , Edited by admin on Mon Mar 31 17:50:59 GMT 2025
PRIMARY Merck Index
WIKIPEDIA
FLUTICASONE PROPIONATE
Created by admin on Mon Mar 31 17:50:59 GMT 2025 , Edited by admin on Mon Mar 31 17:50:59 GMT 2025
PRIMARY
ChEMBL
CHEMBL1473
Created by admin on Mon Mar 31 17:50:59 GMT 2025 , Edited by admin on Mon Mar 31 17:50:59 GMT 2025
PRIMARY
DAILYMED
O2GMZ0LF5W
Created by admin on Mon Mar 31 17:50:59 GMT 2025 , Edited by admin on Mon Mar 31 17:50:59 GMT 2025
PRIMARY
SMS_ID
100000092718
Created by admin on Mon Mar 31 17:50:59 GMT 2025 , Edited by admin on Mon Mar 31 17:50:59 GMT 2025
PRIMARY
DRUG CENTRAL
1225
Created by admin on Mon Mar 31 17:50:59 GMT 2025 , Edited by admin on Mon Mar 31 17:50:59 GMT 2025
PRIMARY
NSC
759889
Created by admin on Mon Mar 31 17:50:59 GMT 2025 , Edited by admin on Mon Mar 31 17:50:59 GMT 2025
PRIMARY
FDA UNII
O2GMZ0LF5W
Created by admin on Mon Mar 31 17:50:59 GMT 2025 , Edited by admin on Mon Mar 31 17:50:59 GMT 2025
PRIMARY
DRUG BANK
DB00588
Created by admin on Mon Mar 31 17:50:59 GMT 2025 , Edited by admin on Mon Mar 31 17:50:59 GMT 2025
PRIMARY
USAN
W-145
Created by admin on Mon Mar 31 17:50:59 GMT 2025 , Edited by admin on Mon Mar 31 17:50:59 GMT 2025
PRIMARY
CAS
80474-14-2
Created by admin on Mon Mar 31 17:50:59 GMT 2025 , Edited by admin on Mon Mar 31 17:50:59 GMT 2025
PRIMARY
RS_ITEM_NUM
1285873
Created by admin on Mon Mar 31 17:50:59 GMT 2025 , Edited by admin on Mon Mar 31 17:50:59 GMT 2025
PRIMARY
RXCUI
50121
Created by admin on Mon Mar 31 17:50:59 GMT 2025 , Edited by admin on Mon Mar 31 17:50:59 GMT 2025
PRIMARY RxNorm
IUPHAR
7080
Created by admin on Mon Mar 31 17:50:59 GMT 2025 , Edited by admin on Mon Mar 31 17:50:59 GMT 2025
PRIMARY
NCI_THESAURUS
C29061
Created by admin on Mon Mar 31 17:50:59 GMT 2025 , Edited by admin on Mon Mar 31 17:50:59 GMT 2025
PRIMARY
EPA CompTox
DTXSID8045511
Created by admin on Mon Mar 31 17:50:59 GMT 2025 , Edited by admin on Mon Mar 31 17:50:59 GMT 2025
PRIMARY
CHEBI
31441
Created by admin on Mon Mar 31 17:50:59 GMT 2025 , Edited by admin on Mon Mar 31 17:50:59 GMT 2025
PRIMARY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966